Mary Anne Heino: Yeah. It’s $0.14 impact in the back half of the year. So it was a $50 to $70 million. So yes, that would be the equivalent would be — that would have been the equivalent yes, but or don’t include
Larry Solow: Absolutely. Okay. Just a question on — just a follow-up on just on adoption trends. As you go forward and more recently, are you — is it more expansion on existing doctors you’re getting new doctors scans averages are they continuing to go upwards. And then also in terms of — are you seeing more penetration for initial staging of high-risk patients or suspected by recurrent is there a different pay or you have better penetration?
Mary Anne Heino: Larry, that was about 25 questions in one. I’m going to turn it to Paul.
Paul Blanchfield: Thank you. Larry, good morning. Thanks for the question. I think where we see PYLARIFY and really the added penetration, I think this has really followed a trend that we had expected. If we go back to what we talked about last year, we were really about adding additional accounts, and those were metrics that we shared as we were having more imaging centers, whether they be government facilities, hospitals or freestanding imaging centers, adopt PYLARIFY and be able to offer it to their referring physicians. I think what we’ve seen over the last couple of months and certainly in the second quarter was the — there’s only so many accounts we’re going to be adding. And so our real focus has been driving adoption and raising awareness amongst referring physicians.
That does include new physicians that have not yet adopted PSMA PET imaging, including with PYLARIFY. But I would say it’s increasingly ensuring those physicians understand the breadth of patients with which they can prescribe and the benefits of PSMA pad with PYLARIFY. Naturally, the recurrent setting, where we had a previous conventional imaging pet imaging agent approved in that setting was an early adopter. I think we’ve seen increased adoption in the initial staging and going down from high — very high risk to high risk to intermediate unfavorable, as we would expect in a launch. And then naturally, with Pluvicto being approved last year, we’ve also seen a like minor some scans to support that patient selection. So, I think things are generally following the trend that we would expect where that existing account growth or the activation of referral physicians has really been a key focus of ours.
And as Bob mentioned, we’ve made investments in our sales and marketing demand-generating activities, which we think is appropriate given where we are, but also demonstrates the confidence in the growth potential to not only continue to grow this $1.2 billion category, but also expand what the potential is as guidelines and medical practice continues to evolve.
Mary Anne Heino: That was about 23 of 25 question.
Operator: Thank you. And for the next question, it comes from the line of David Turkaly from JMP Securities. David, your line is open.
David Turkaly: Hey good morning. Just looking at slide seven in the deck, and you talked a lot about the commercial and clinical differentiation on PYLARIFY, but we look at the warnings and precautions in the commentary there, and I really just have to get your thoughts on do docs — what do you assume that they’re going to look at that and change their practice, or do you have any precedent to look at where there was something like that clinically or a different label that actually impacted practice? Or do you feel like the docs are going to heed these warnings, or is it something that — any thoughts that you have on sort of what impact that might have would be great.
Mary Anne Heino: Yeah. I think it’s a really bear question, and I’ll answer it this way. We are absolutely committed as we always have then as a company to operating within our kind of field of play, which is the United States reg market is your package insert your label. That is the basis for your right for promotion, the basis for your right for shares, especially from a commercial perspective, from sharing clinical data about your products, and we are incredibly committed to that. I think your comment about will doctors really changed their mind based on a single part of the label. I don’t think so. I think what’s much more relevant here, is the clinical experience that physicians already have with PYLARIFY. We’ve been in the market is now over two years.
